These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38267664)

  • 1. Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Imano H; Ogawa S
    Osteoporos Int; 2024 May; 35(5):805-818. PubMed ID: 38267664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2022 Jul; 160():116396. PubMed ID: 35351673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Osteoporos Int; 2022 May; 33(5):1097-1108. PubMed ID: 35022812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid.
    Sugiyama T; Suzuki S; Yoshida T; Suyama K; Tanaka T; Sueishi M; Tatsuno I
    Gend Med; 2010 Jun; 7(3):218-29. PubMed ID: 20638627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoids Are Associated with an Increased Risk for Vertebral Fracture in Patients with Rheumatoid Arthritis.
    Kim D; Cho SK; Park B; Jang EJ; Bae SC; Sung YK
    J Rheumatol; 2018 May; 45(5):612-620. PubMed ID: 29545455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of symptomatic vertebral fracture with high-dose glucocorticoid treatment in the Chiba-Shimoshizu Rheumatic Cohort between 1986 and 2006.
    Sugiyama T; Tatsuno I; Suzuki S; Yoshida T; Tanaka T; Sueishi M; Saito Y
    Endocr J; 2009; 56(4):591-9. PubMed ID: 19352047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fracture risk with intermittent high-dose oral glucocorticoid therapy.
    De Vries F; Bracke M; Leufkens HG; Lammers JW; Cooper C; Van Staa TP
    Arthritis Rheum; 2007 Jan; 56(1):208-14. PubMed ID: 17195223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of fractures among patients receiving medications for type 2 diabetes or chronic obstructive pulmonary disease and glucocorticoid users according to the National Claims Database in Japan.
    Fujiwara S; Ishii S; Hamasaki T; Okimoto N
    Arch Osteoporos; 2021 Jun; 16(1):106. PubMed ID: 34191131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Systemic Glucocorticoid Use on Fracture Risk: A Population-Based Study.
    Koh JW; Kim J; Cho H; Ha YC; Kim TY; Lee YK; Kim HY; Jang S
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):562-570. PubMed ID: 32981298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study.
    Amiche MA; Abtahi S; Driessen JHM; Vestergaard P; de Vries F; Cadarette SM; Burden AM
    Arch Osteoporos; 2018 Mar; 13(1):30. PubMed ID: 29552730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hip and vertebral fracture risk after initiating antidiabetic drugs in Japanese elderly: a nationwide study.
    Tamaki J; Ogawa S; Fujimori K; Ishii S; Nakatoh S; Okimoto N; Kamiya K; Iki M
    J Bone Miner Metab; 2023 Jan; 41(1):29-40. PubMed ID: 36517653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip and vertebral fracture: analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
    Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
    Arch Osteoporos; 2021 Sep; 16(1):130. PubMed ID: 34510296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis.
    Mori Y; Izumiyama T; Baba K; Mori N; Fujii H; Ishii T; Itoi E
    J Orthop Surg Res; 2020 Jul; 15(1):290. PubMed ID: 32727595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
    Lin SM; Yang SH; Liang CC; Huang HK
    Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of fracture in women with glucocorticoid requiring diseases is independent from glucocorticoid use: An analysis on a nation-wide database.
    Adami G; Gatti D; Rossini M; Giollo A; Gatti M; Bertoldo F; Bertoldo E; Mudano AS; Saag KG; Viapiana O; Fassio A
    Bone; 2024 Feb; 179():116958. PubMed ID: 37949390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age, initial dose and dose increase are independent risk factors for symptomatic vertebral fractures in glucocorticoid-treated male patients.
    Sugiyama T; Suzuki S; Yoshida T; Mayama T; Hashimoto N; Suyama K; Tanaka T; Sueishi M; Tatsuno I
    Intern Med; 2011; 50(8):817-24. PubMed ID: 21498928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of benign prostatic hyperplasia on the development of spine, hip, and wrist fractures.
    Yang SC; Chiu YC; Liu PH; Hsieh TJ; Kao YH; Tu YK
    Osteoporos Int; 2019 May; 30(5):1043-1049. PubMed ID: 30706096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-hip and non-vertebral fractures: the neglected fracture sites.
    Holloway KL; Henry MJ; Brennan-Olsen SL; Bucki-Smith G; Nicholson GC; Korn S; Sanders KM; Pasco JA; Kotowicz MA
    Osteoporos Int; 2016 Mar; 27(3):905-913. PubMed ID: 26438309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.